- Phase I Clinical Trial of Paclitaxel Plus Ifosfamide for the Patients with Refractory Ovarian Cancer
-
Saw HS, Lee JK
- KMID: 1815306
- J Korean Cancer Assoc.
- 2000 Oct;32(5):895-903.
PURPOSE: Patients with advanced ovarian carcinoma and refractory to platinum based chemotherapy have a very poor prognosis and effective salvage regimens are needed. This study was conducted in order to... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Nasal Cellulose Powder in the Symptomatic Treatment of Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Trial
-
Manuyakorn W, Klangkalya N, Kamchaisatian W, Benjaponpita S, Sasisakulporn C, Jotikasthira W
- KMID: 2383993
- Allergy Asthma Immunol Res.
- 2017 Sep;9(5):446-452.
- doi: 10.4168/aair.2017.9.5.446
PURPOSE: Nasal Cellulose Powder (NCP), which can prevent from binding an allergen to nasal mucosa, may reduce allergic rhinitis (AR) symptoms in dust mite-sensitized children. This study was conducted to... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
-
Lee HJ, Heo DS, Cho JY, Han SW, Chang HJ, Yi HG, Kim TE, Lee SH, Oh DY, Im SA, Jang IJ, Bang YJ
- KMID: 2167688
- Cancer Res Treat.
- 2014 Jul;46(3):234-242.
PURPOSE: The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A,... -
- CITED
-
- Close
- SHARE
-
- Close
- Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
-
Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz , Vaughn DJ
- KMID: 2344082
- Cancer Res Treat.
- 2016 Jul;48(3):1084-1091.
- doi: 10.4143/crt.2015.405
PURPOSE: We sought to investigate the safety and efficacy of gemcitabine, cisplatin, and lapatinib (GCL) as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) planned for radical cystectomy. MATERIALS AND... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
-
Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY
- KMID: 2464398
- Cancer Res Treat.
- 2019 Apr;51(2):510-518.
- doi: 10.4143/crt.2018.226
PURPOSE: The signal transducer and activator of transcription 3 (STAT3) signaling pathway might be a promising therapeutic target for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This study was a multicenter, open-label,... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase I and Pharmacokinetic Study of Intraoperative Intraperitoneal Heptaplatin in Patients with Surgically Resected Advanced Gastric Cancer
-
Yu W, Chung HY, Park SH, Cho YB, Lim YS
- KMID: 1807218
- Cancer Res Treat.
- 2003 Feb;35(1):25-29.
PURPOSE: Heptaplatin, a new platinum analog, has favorable toxicity profiles and antitumor activity, comparable to those of cisplatin, in the treatment of gastric cancer. This study was designed to define... -
- CITED
-
- Close
- SHARE
-
- Close
- A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
-
Kim JE, Yoon DH, Jang G, Lee DH, Kim S, Park CS, Huh J, Kim WS, Park J, Lee JH, Lee SI, Suh C
- KMID: 2251971
- Korean J Hematol.
- 2012 Mar;47(1):53-59.
- doi: 10.5045/kjh.2012.47.1.53
BACKGROUND: Bortezomib targets molecular dysregulation of nuclear factor-kappaB activation and cell cycle control, which are characteristic features of diffuse large B-cell lymphoma (DLBCL). We evaluated the safety and efficacy of... -
- CITED
-
- Close
- SHARE
-
- Close
- An open trial of topiramate as add-on therapy in children with refractory epilepsy
-
Woo YJ, Lee HS, Ju SW, Choi YR, Kim JH
- KMID: 2172462
- Chonnam Med J.
- 1999 Dec;35(4):445-452.
28 cases of intractable childhood epilepsy aged of 1 year 3 months through 17 years 5 months have been treated with topiramate (TPM) as a add-on base from April, 1999.... -
- CITED
-
- Close
- SHARE
-
- Close
- Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs
-
Kerbel RS
- KMID: 2166019
- Cancer Res Treat.
- 2007 Dec;39(4):150-159.
One of the most significant developments in medical oncology practice has been the approval of various antiangiogenic drugs for the treatment of a number of different malignancies. These drugs include... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
-
Kim TM, Lee KW, Oh DY, Lee JS, Im SA, Kim DW, Han SW, Kim YJ, Kim TY, Kim JH, Han H, Kim WH, Bang YJ
- KMID: 2417872
- Cancer Res Treat.
- 2018 Jul;50(3):835-842.
- doi: 10.4143/crt.2017.303
PURPOSE: Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity againstwild type of epidermal growth factorreceptor(EGFR) family kinases including EGFR, HER2, and HER4... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
-
Oh DY, Doi T, Shirao K, Lee KW, Park SR, Chen Y, Yang L, Valota O, Bang YJ
- KMID: 2403387
- Cancer Res Treat.
- 2015 Oct;47(4):687-696.
- doi: 10.4143/crt.2014.225
PURPOSE: This phase I trial evaluated the question of whether the standard starting dose of axitinib could be administered in combination with therapeutic doses of cisplatin/capecitabine in patients with previously... -
- CITED
-
- Close
- SHARE
-
- Close
- TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
-
Bang YJ, Takano T, Lin CC, Fasanmade , Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T
- KMID: 2411129
- Cancer Res Treat.
- 2018 Apr;50(2):398-404.
- doi: 10.4143/crt.2017.074
PURPOSE: This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of TAK-264 in Asian patients with advanced gastrointestinal (GI) carcinoma or metastatic or... -
- CITED
-
- Close
- SHARE
-
- Close
- Bright Light Therapy in the Morning or at Mid-Day in the Treatment of Non-Seasonal Bipolar Depressive Episodes (LuBi): Study Protocol for a Dose Research Phase I / II Trial
-
Geoffroy P, El Abbassi EMB, Maruani J, Etain B, Lejoyeux M, Amad A, Courtet P, Dubertret , Gorwood P, Vaiva G, Bellivier , Chevret S
- KMID: 2434769
- Psychiatry Investig.
- 2018 Dec;15(12):1188-1202.
- doi: 10.30773/pi.2018.09.27.1
OBJECTIVE: This study protocol aims to determine, using a rigorous approach in patients with bipolar disorder (BD) and non-seasonal major depressive episode (MDE), the characteristics of bright light therapy (BLT)... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Outcome of Adult Acute Lymphocytic Leukemia with VPD (L) Regimen: analysis of Prognostic Factors
-
Park SR, Kim JH, Kim DY, Lee SH, Lee SY, Choi IS, Yoon SS, Park SY, Kim BG, Kim NK
- KMID: 759630
- Korean J Intern Med.
- 2003 Mar;18(1):21-28.
BACKGROUND: Because of the relative paucity of data regarding the clinical outcome in adult patients with acute lymphocytic leukemia (ALL) in Korea, we analyzed clinical courses in adult ALL patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study
-
Lee HY, Chung WJ, Jeon HK, Seo HS, Choi DJ, Jeon ES, Kim JJ, Shin JH, Kang SM, Lim SC, Baek SH
- KMID: 2373803
- Korean J Intern Med.
- 2016 Mar;31(2):277-287.
- doi: 10.3904/kjim.2015.043
BACKGROUND/AIMS: We evaluated the association between coding region variants of adrenergic receptor genes and therapeutic effect in patients with congestive heart failure (CHF). METHODS: One hundred patients with stable CHF (left... -
- CITED
-
- Close
- SHARE
-
- Close
